{"title": "An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)", "doi": "10.1101/2020.03.19.20038984", "citation_id": "2020.03.19.20038984v1", "date": "2020-03-23", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.19.20038984", "abstract": "<p>Background: The novel coronavirus pneumonia (COVID-19) outbreak has caused a global pandemic, however, effective antiviral therapeutics are still unavailable. \n\nMethods: Our study (NCT04252885), designated as ELACOI, was an exploratory randomized (2:2:1) and controlled one, exploring the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy treating mild/moderate COVID-19 patients. \n\nResults:  This study successful enrolled 44 patients with mild/moderate COVID-19, with 21 randomly assigned to receive LPV/r, 16 to arbidol and 7 to no antiviral medication as control. Baseline characteristics of three groups were comparable. The median time of positive-to-negative conversion of SARS-CoV-2 nucleic acid was 8.5 (IQR 3, 13) days in the LPV/r group, 7 (IQR 3, 10.5) days in the arbidol group and 4 (IQR 3, 10.5) days in the control group (P=0.751). The positive-to-negative conversion rates of SARS-CoV-2 nucleic acid at day 7 and 14 did not show significant differences in the LPV/r group (42.9%, 76.2%), the arbidol group (62.5%, 87.5%) and the control group (71.4%, 71.4%) (all P&gt;0.53). No statistical differences were found among three groups in the rates of antipyresis, cough alleviation, improvement of chest CT or the deterioration rate of clinical status (all P &gt; 0.05). Overall, 5 (23.8%) patients in the LPV/r group experienced adverse events during the follow-up period. No apparent adverse events occurred in the arbidol or control group.\n\nConclusion: LPV/r or arbidol monotherapy seems little benefit for improving the clinical outcome of mild/moderate COVID-19. LPV/r might lead to more adverse events. Due to the limitation of small sample size, further verification is needed in the future.</p>", "twitter_description": "Background: The novel coronavirus pneumonia (COVID-19) outbreak has caused a global pandemic, however, effective antiviral therapeutics are still unavailable. Methods: Our study ([NCT04252885][1]), designated as ELACOI, was an exploratory randomized (2:2:1) and controlled one, exploring the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy treating mild/moderate COVID-19 patients. Results: This study successful enrolled 44 patients with mild/moderate COVID-19, with 21 randomly assigned to receive LPV/r, 16 to arbidol and 7 to no antiviral medication as control. Baseline characteristics of three groups were comparable. The median time of positive-to-negative conversion of SARS-CoV-2 nucleic acid was 8.5 (IQR 3, 13) days in the LPV/r group, 7 (IQR 3, 10.5) days in the arbidol group and 4 (IQR 3, 10.5) days in the control group (P=0.751). The positive-to-negative conversion rates of SARS-CoV-2 nucleic acid at day 7 and 14 did not show significant differences in the LPV/r group (42.9%, 76.2%), the arbidol group (62.5%, 87.5%) and the control group (71.4%, 71.4%) (all P>0.53). No statistical differences were found among three groups in the rates of antipyresis, cough alleviation, improvement of chest CT or the deterioration rate of clinical status (all P > 0.05). Overall, 5 (23.8%) patients in the LPV/r group experienced adverse events during the follow-up period. No apparent adverse events occurred in the arbidol or control group. Conclusion: LPV/r or arbidol monotherapy seems little benefit for improving the clinical outcome of mild/moderate COVID-19. LPV/r might lead to more adverse events. Due to the limitation of small sample size, further verification is needed in the future.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Clinical Trial\n\nNCT04252885\n\n### Funding Statement\n\nThis study was supported by Chinese 13th Five-Year National Science and technology major project\uff082018ZX10302103-002, 2017ZX10202102-003-004\uff09, and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021).\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data included in this study are available upon request by contact with the corresponding author.\n\n [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04252885&atom=%2Fmedrxiv%2Fearly%2F2020%2F03%2F23%2F2020.03.19.20038984.atom", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/23/2020.03.19.20038984.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.19.20038984v1", "access_rights": "restricted", "authors": ["Yueping Li", "Zhiwei Xie", "Weiyin Lin", "Weiping Cai", "Chunyan Wen", "Yujuan Guan", "Xiaoneng Mo", "Jian Wang", "Yaping Wang", "Ping Peng", "Xudan Chen", "Wenxin Hong", "Guangming Xiao", "Jinxin Liu", "Lieguang Zhang", "Fengyu Hu", "Feng Li", "Feng Li", "Fuchun Zhang", "Xilong Deng", "Linghua Li"]}